Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.